Prestige Consumer Healthcare acquires LaCorium Health, posts $1.1B in annual revenue
What's the deal? Prestige Consumer Healthcare (NYSE: PBH), a Tarrytown, New York-based consumer health company, reported fiscal year 2026 results and announced it has agreed to acquire LaCorium HealthDealroom has a profile for this one. Try Dealroom →, an Australian therapeutic skin care company. The company posted $1,088.7 million in annual revenue and $246.4 million in free cash flow for the fiscal year ended March 31, 2026.
Fourth-quarter revenue came in at $281.6 million, down 5% from $296.5 million in the same period a year earlier. Diluted earnings per share for the full year were $3.91, with adjusted diluted EPS at $4.38.
Why now? Prestige is looking to expand its international footprint through the LaCorium deal, which adds an Australian skin care brand to its portfolio. The company described its fiscal 2026 as a demonstration of "the resilience of our business model in a challenging consumer backdrop."
Strong growth from brands like Fleet, Dramamine, and Hydralyte in its gastrointestinal category helped offset headwinds elsewhere — particularly limited production capacity for its Clear Eyes product and shipping disruptions in the Middle East during the fourth quarter.
What could go wrong? The revenue decline is notable. Full-year revenue fell 4.3% from $1,137.8 million the prior year, driven largely by lower Eye & Ear Care category sales. The company's limited ability to supply demand for Clear Eyes remains an ongoing challenge.
Excluding foreign currency effects, the picture looks slightly worse: fourth-quarter revenue dropped 6.4% year over year, and full-year revenue fell 4.5%. Integrating LaCorium while managing existing supply constraints adds further execution risk.
The signal: LaCorium Health, classified as a "breakout" stage company by Dealroom, represents the kind of proven-but-scaling brand that mid-cap acquirers increasingly target to diversify beyond saturated domestic categories. With Prestige's organic growth outlook capped at 1% to 3% and core product lines like Clear Eyes constrained by supply limitations, the acquisition underscores a broader playbook among consumer health incumbents: buying international therapeutic niches to compensate for stalling legacy portfolios.
Read more: globenewswire.com
